SparkleNCT07287982
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 28 → 46 locations
- Notable Eligibility criteria expanded, about 10 words
- Trial sites expanded: 23 → 28 locations
- Secondary endpoints: details revised at 1 of 3 entries
- Minor Site details revised at 1 of 23 sitesv12
- Minor Study sites: 24 to 23v11
- Minor Site details revised at 1 of 24 sitesv10
- Minor Trial sites expanded: 17 → 24 locationsv9
- Minor Site details revised at 1 of 17 sitesv8
- Minor Site details revised at 1 of 17 sitesv7
- Minor Site details revised at 1 of 17 sitesv6
- Minor Site contacts updated at 1 of 17 sitesv5
- Minor Study sites: 15 to 17v4
- Minor Study sites: 2 to 15v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of AEs
Timeframe: Up to 124 weeks
Incidence of SAEs
Timeframe: Up to 124 weeks
Change in RHS total score from baseline to week 24 of the double blinded treatment period (DBTP)
Timeframe: Up to 24 weeks
Secondary (3)
Change from baseline over time for the 6MWT - distance and fatigue index
ARGX-119 serum concentrations over time
Incidence of antidrug antibodies (ADA) against ARGX-119
Arms and interventions
DBTP - ARGX-119 IVExperimental
Participants receive ARGX-119 IV during the DBTP
DBTP - Placebo IVPlacebo comparator
Participants receive placebo IV during the DBTP
ATEP - ARGX-119 IVPlacebo comparator
Participants receive ARGX-119 IV during the ATEP. Participants from ARGX-119 IV arm in the DBTP will receive placebo once to maintain the DBTP blinding
Biologicals: ARGX-119 IV
Other: Placebo IV
Sites
46 sites in 10 countries
United States 16, United Kingdom 7, Italy 5, Germany 4, Belgium 3, Canada 3, Poland 3, Australia 2, Spain 2, Netherlands 1